S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

Nektar Therapeutics Stock Forecast, Price & News

-0.05 (-1.32%)
(As of 07/1/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
2.37 million shs
Average Volume
3.77 million shs
Market Capitalization
$698.51 million
P/E Ratio
Dividend Yield
Price Target

Nektar Therapeutics MarketRank™ Forecast

Analyst Rating
2.08 Rating Score
251.1% Upside
$13.17 Price Target
Short Interest
9.47% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.83mentions of Nektar Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$334.28 K Sold Last Quarter
Proj. Earnings Growth
From ($2.31) to ($1.16) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.05 out of 5 stars

Medical Sector

275th out of 1,428 stocks

Pharmaceutical Preparations Industry

131st out of 682 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive NKTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nektar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Nektar Therapeutics logo

About Nektar Therapeutics (NASDAQ:NKTR) Stock

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.

NKTR Stock News Headlines

Nektar promotes internal executive to CFO role
Protect Your Trading Account With Options!
This might be the opposite of what you’ve heard, but the real risk in the market now lies with stock trading… “Options Trading Made Easy” by expert Chuck Hughes will show you how the nature of options trading gives you the chance to profit no matter which way the market trends! Get the e-book today!
Nektar Therapeutics (NASDAQ:NKTR) Shares Up 6.5%
Make Sure Your Alarm Is Set…
This early morning trade is constantly overlooked, but those who use it are retiring early! Hi, I’m trading expert Dave Aquino and with my new guide, “How To Master The Retirement Trade”, you could be taking advantage of it as well! The trade starts at 9:30EST…don’t be late! Get a copy here!
Nektar Therapeutics Reports First Quarter 2022 Financial Results
Why Nektar Shares Are Down Almost 35%
Expert Ratings for Nektar Therapeutics
Why Nektar Shares Are Down 35%
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
12 Analysts


Net Income
$-523.84 million
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$101.91 million
Book Value
$3.68 per share


Free Float
Market Cap
$698.51 million

Social Links

Nektar Therapeutics Frequently Asked Questions

Should I buy or sell Nektar Therapeutics stock right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last year. There are currently 2 sell ratings, 7 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Nektar Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NKTR, but not buy additional shares or sell existing shares.
View analyst ratings for Nektar Therapeutics
or view top-rated stocks.

What is Nektar Therapeutics' stock price forecast for 2022?

12 Wall Street research analysts have issued 1 year price targets for Nektar Therapeutics' shares. Their NKTR stock forecasts range from $3.00 to $54.00. On average, they expect Nektar Therapeutics' stock price to reach $13.17 in the next twelve months. This suggests a possible upside of 251.1% from the stock's current price.
View analysts' price targets for Nektar Therapeutics
or view top-rated stocks among Wall Street analysts.

How has Nektar Therapeutics' stock price performed in 2022?

Nektar Therapeutics' stock was trading at $13.51 at the beginning of 2022. Since then, NKTR shares have decreased by 72.2% and is now trading at $3.75.
View the best growth stocks for 2022 here

When is Nektar Therapeutics' next earnings date?

Nektar Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Nektar Therapeutics

How were Nektar Therapeutics' earnings last quarter?

Nektar Therapeutics (NASDAQ:NKTR) announced its earnings results on Thursday, May, 5th. The biopharmaceutical company reported ($0.49) earnings per share for the quarter, topping analysts' consensus estimates of ($0.72) by $0.23. The biopharmaceutical company had revenue of $24.82 million for the quarter, compared to the consensus estimate of $24.89 million. Nektar Therapeutics had a negative net margin of 476.58% and a negative trailing twelve-month return on equity of 65.64%. The business's revenue for the quarter was up 5.0% on a year-over-year basis. During the same quarter last year, the firm earned ($0.68) EPS.
View Nektar Therapeutics' earnings history

Who are Nektar Therapeutics' key executives?

Nektar Therapeutics' management team includes the following people:
  • Mr. Howard W. Robin, CEO, Pres & Director (Age 69, Pay $2.14M)
  • Mr. Gilbert M. Labrucherie J.D., Sr. VP, CFO & COO (Age 50, Pay $1.49M)
  • Mr. Mark A. Wilson, Sr. VP, Gen. Counsel & Sec. (Age 50, Pay $798.26k)
  • Dr. Jonathan Zalevsky Ph.D., Sr. VP & Chief R&D Officer (Age 47, Pay $1.16M) (LinkedIn Profile)
  • Mr. John P. Northcott, Sr. VP & Chief Commercial Officer (Age 44, Pay $1.07M) (LinkedIn Profile)
  • Ms. Jillian B. Thomsen, Sr. VP of Fin. & Chief Accounting Officer (Age 56) (LinkedIn Profile)
  • Mr. Robert Bacci, Sr. VP of HR and Facilities
  • Ms. Jennifer Ruddock, Sr. VP of Strategy & Corp. Affairs
  • Dr. Mary Tagliaferri L.Ac., M.D., Sr. VP & Exec. Clinical Fellow (Age 56)
  • Dr. Brian L. Kotzin M.D., Sr. VP of Clinical Devel. & Head of Immunology (Age 73)

What is Howard W. Robin's approval rating as Nektar Therapeutics' CEO?

46 employees have rated Nektar Therapeutics CEO Howard W. Robin on Glassdoor.com. Howard W. Robin has an approval rating of 81% among Nektar Therapeutics' employees.

What other stocks do shareholders of Nektar Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nektar Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Gilead Sciences (GILD), Intel (INTC), Pfizer (PFE), Advanced Micro Devices (AMD), Bristol-Myers Squibb (BMY), Netflix (NFLX) and Incyte (INCY).

What is Nektar Therapeutics' stock symbol?

Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR."

How do I buy shares of Nektar Therapeutics?

Shares of NKTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nektar Therapeutics' stock price today?

One share of NKTR stock can currently be purchased for approximately $3.75.

How much money does Nektar Therapeutics make?

Nektar Therapeutics (NASDAQ:NKTR) has a market capitalization of $698.51 million and generates $101.91 million in revenue each year. The biopharmaceutical company earns $-523.84 million in net income (profit) each year or ($2.670010) on an earnings per share basis.

How many employees does Nektar Therapeutics have?

Nektar Therapeutics employs 740 workers across the globe.

When was Nektar Therapeutics founded?

Nektar Therapeutics was founded in 1990.

How can I contact Nektar Therapeutics?

Nektar Therapeutics' mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The official website for Nektar Therapeutics is www.nektar.com. The biopharmaceutical company can be reached via phone at (415) 482-5300, via email at investors@nektar.com, or via fax at 415-339-5300.

This page (NASDAQ:NKTR) was last updated on 7/3/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.